CovidFranceV1, Main, Exploration, bibRecord, 000713

Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions.

Identifieur interne : 000713 ( Main/Exploration ); précédent : 000712; suivant : 000714

Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions.

Auteurs : Peter Valent [Autriche] ; Cem Akin ; Patrizia Bonadonna [Italie] ; Knut Brockow [Allemagne] ; Marek Niedoszytko [Pologne] ; Boguslaw Nedoszytko [Pologne] ; Joseph H. Butterfield ; Ivan Alvarez-Twose [Espagne] ; Karl Sotlar [Autriche] ; Juliana Schwaab [Allemagne] ; Mohamad Jawhar [Allemagne] ; Andreas Reiter [Allemagne] ; Mariana Castells ; Wolfgang R. Sperr [Autriche] ; Hanneke C. Kluin-Nelemans [Pays-Bas] ; Olivier Hermine [France] ; Jason Gotlib ; Roberta Zanotti [Italie] ; Sigurd Broesby-Olsen [Danemark] ; Hans-Peter Horny [Allemagne] ; Massimo Triggiani [Italie] ; Frank Siebenhaar [Allemagne] ; Alberto Orfao [Espagne] ; Dean D. Metcalfe [Allemagne] ; Michel Arock [France] ; Karin Hartmann [Suisse]

Source :

The Journal of allergy and clinical immunology [ 1097-6825 ] ; 2020.

RBID : pubmed:32561389

Descripteurs français

KwdFr :
- Agonistes myélo-ablatifs (effets indésirables), Antihistaminiques (usage thérapeutique), Betacoronavirus (immunologie), Betacoronavirus (pathogénicité), Comorbidité (MeSH), Diphosphonates (usage thérapeutique), Expertise (MeSH), Facteurs de risque (MeSH), Glucocorticoïdes (effets indésirables), Humains (MeSH), Immunosuppresseurs (effets indésirables), Infections à coronavirus (anatomopathologie), Infections à coronavirus (diagnostic), Infections à coronavirus (épidémiologie), Mastocytes (anatomopathologie), Mastocytes (effets des médicaments et des substances chimiques), Mastocytes (immunologie), Mastocytose cutanée (anatomopathologie), Mastocytose cutanée (diagnostic), Mastocytose cutanée (traitement médicamenteux), Mastocytose cutanée (épidémiologie), Mastocytose généralisée (anatomopathologie), Mastocytose généralisée (diagnostic), Mastocytose généralisée (traitement médicamenteux), Mastocytose généralisée (épidémiologie), Médecine de précision (méthodes), Pandémies (MeSH), Pneumopathie virale (anatomopathologie), Pneumopathie virale (diagnostic), Pneumopathie virale (épidémiologie), Prise en charge de la maladie (MeSH), Vitamine D (usage thérapeutique).
MESH :
- anatomopathologie : Infections à coronavirus, Mastocytes, Mastocytose cutanée, Mastocytose généralisée, Pneumopathie virale.
- diagnostic : Infections à coronavirus, Mastocytose cutanée, Mastocytose généralisée, Pneumopathie virale.
- effets des médicaments et des substances chimiques : Mastocytes.
- effets indésirables : Agonistes myélo-ablatifs, Glucocorticoïdes, Immunosuppresseurs.
- immunologie : Betacoronavirus, Mastocytes.
- méthodes : Médecine de précision.
- pathogénicité : Betacoronavirus.
- traitement médicamenteux : Mastocytose cutanée, Mastocytose généralisée.
- usage thérapeutique : Antihistaminiques, Diphosphonates, Vitamine D.
- épidémiologie : Infections à coronavirus, Mastocytose cutanée, Mastocytose généralisée, Pneumopathie virale.
- Comorbidité, Expertise, Facteurs de risque, Humains, Pandémies, Prise en charge de la maladie.

English descriptors

KwdEn :
- Betacoronavirus (immunology), Betacoronavirus (pathogenicity), Comorbidity (MeSH), Coronavirus Infections (diagnosis), Coronavirus Infections (epidemiology), Coronavirus Infections (pathology), Diphosphonates (therapeutic use), Disease Management (MeSH), Expert Testimony (MeSH), Glucocorticoids (adverse effects), Histamine Antagonists (therapeutic use), Humans (MeSH), Immunosuppressive Agents (adverse effects), Mast Cells (drug effects), Mast Cells (immunology), Mast Cells (pathology), Mastocytosis, Cutaneous (diagnosis), Mastocytosis, Cutaneous (drug therapy), Mastocytosis, Cutaneous (epidemiology), Mastocytosis, Cutaneous (pathology), Mastocytosis, Systemic (diagnosis), Mastocytosis, Systemic (drug therapy), Mastocytosis, Systemic (epidemiology), Mastocytosis, Systemic (pathology), Myeloablative Agonists (adverse effects), Pandemics (MeSH), Pneumonia, Viral (diagnosis), Pneumonia, Viral (epidemiology), Pneumonia, Viral (pathology), Precision Medicine (methods), Risk Factors (MeSH), Vitamin D (therapeutic use).
MESH :
- chemical , adverse effects : Glucocorticoids, Immunosuppressive Agents, Myeloablative Agonists.
- chemical , therapeutic use : Diphosphonates, Histamine Antagonists, Vitamin D.
- diagnosis : Coronavirus Infections, Mastocytosis, Cutaneous, Mastocytosis, Systemic, Pneumonia, Viral.
- drug effects : Mast Cells.
- drug therapy : Mastocytosis, Cutaneous, Mastocytosis, Systemic.
- epidemiology : Coronavirus Infections, Mastocytosis, Cutaneous, Mastocytosis, Systemic, Pneumonia, Viral.
- immunology : Betacoronavirus, Mast Cells.
- methods : Precision Medicine.
- pathogenicity : Betacoronavirus.
- pathology : Coronavirus Infections, Mast Cells, Mastocytosis, Cutaneous, Mastocytosis, Systemic, Pneumonia, Viral.
- Comorbidity, Disease Management, Expert Testimony, Humans, Pandemics, Risk Factors.

Abstract

The coronavirus disease 2019 (COVID-19) (caused by severe acute respiratory syndrome coronavirus 2) pandemic has massively distorted our health care systems and caused catastrophic consequences in our affected communities. The number of victims continues to increase, and patients at risk can only be protected to a degree, because the virulent state may be asymptomatic. Risk factors concerning COVID-19-induced morbidity and mortality include advanced age, an impaired immune system, cardiovascular or pulmonary diseases, obesity, diabetes mellitus, and cancer treated with chemotherapy. Here, we discuss the risk and impact of COVID-19 in patients with mastocytosis and mast cell activation syndromes. Because no published data are yet available, expert opinions are, by necessity, based on case experience and reports from patients. Although the overall risk to acquire the severe acute respiratory syndrome coronavirus 2 may not be elevated in mast cell disease, certain conditions may increase the risk of infected patients to develop severe COVID-19. These factors include certain comorbidities, mast cell activation-related events affecting the cardiovascular or bronchopulmonary system, and chemotherapy or immunosuppressive drugs. Therefore, such treatments should be carefully evaluated on a case-by-case basis during a COVID-19 infection. In contrast, other therapies, such as anti-mediator-type drugs, venom immunotherapy, or vitamin D, should be continued. Overall, patients with mast cell disorders should follow the general and local guidelines in the COVID-19 pandemic and advice from their medical provider.

DOI: 10.1016/j.jaci.2020.06.009
PubMed: 32561389
PubMed Central: PMC7297685

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000C96
to stream Main, to step Curation: 000C96

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions.</title>
<author><name sortKey="Valent, Peter" sort="Valent, Peter" uniqKey="Valent P" first="Peter" last="Valent">Peter Valent</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine I, Division of Haematology and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria. Electronic address: peter.valent@meduniwien.ac.at.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Internal Medicine I, Division of Haematology and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Akin, Cem" sort="Akin, Cem" uniqKey="Akin C" first="Cem" last="Akin">Cem Akin</name>
<affiliation><nlm:affiliation>Division of Allergy and Clinical Immunology, University of Michigan, Ann Arbor, Mich.</nlm:affiliation>
<wicri:noCountry code="subField">Mich</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Bonadonna, Patrizia" sort="Bonadonna, Patrizia" uniqKey="Bonadonna P" first="Patrizia" last="Bonadonna">Patrizia Bonadonna</name>
<affiliation wicri:level="1"><nlm:affiliation>Allergy Unit, Verona University Hospital, Verona, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Allergy Unit, Verona University Hospital, Verona</wicri:regionArea>
<wicri:noRegion>Verona</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brockow, Knut" sort="Brockow, Knut" uniqKey="Brockow K" first="Knut" last="Brockow">Knut Brockow</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Dermatology and Allergy Biederstein, Technical University of Munich, Munich, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Dermatology and Allergy Biederstein, Technical University of Munich, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
<orgName type="university">Université Louis-et-Maximilien de Munich</orgName>
</affiliation>
</author>
<author><name sortKey="Niedoszytko, Marek" sort="Niedoszytko, Marek" uniqKey="Niedoszytko M" first="Marek" last="Niedoszytko">Marek Niedoszytko</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Allergology, Medical University of Gdansk, Gdansk, Poland.</nlm:affiliation>
<country xml:lang="fr">Pologne</country>
<wicri:regionArea>Department of Allergology, Medical University of Gdansk, Gdansk</wicri:regionArea>
<wicri:noRegion>Gdansk</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Nedoszytko, Boguslaw" sort="Nedoszytko, Boguslaw" uniqKey="Nedoszytko B" first="Boguslaw" last="Nedoszytko">Boguslaw Nedoszytko</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, Medical University of Gdansk, Gdansk, Poland.</nlm:affiliation>
<country xml:lang="fr">Pologne</country>
<wicri:regionArea>Department of Dermatology, Medical University of Gdansk, Gdansk</wicri:regionArea>
<wicri:noRegion>Gdansk</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Butterfield, Joseph H" sort="Butterfield, Joseph H" uniqKey="Butterfield J" first="Joseph H" last="Butterfield">Joseph H. Butterfield</name>
<affiliation><nlm:affiliation>Mayo Clinic, Division of Allergic Diseases, Rochester, Minn.</nlm:affiliation>
<wicri:noCountry code="subField">Minn</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Alvarez Twose, Ivan" sort="Alvarez Twose, Ivan" uniqKey="Alvarez Twose I" first="Ivan" last="Alvarez-Twose">Ivan Alvarez-Twose</name>
<affiliation wicri:level="1"><nlm:affiliation>Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast) and CIBERONC, Hospital Virgen del Valle, Toledo, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast) and CIBERONC, Hospital Virgen del Valle, Toledo</wicri:regionArea>
<wicri:noRegion>Toledo</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sotlar, Karl" sort="Sotlar, Karl" uniqKey="Sotlar K" first="Karl" last="Sotlar">Karl Sotlar</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Pathology, Paracelsus Medical University Salzburg, Salzburg, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Institute of Pathology, Paracelsus Medical University Salzburg, Salzburg</wicri:regionArea>
<wicri:noRegion>Salzburg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schwaab, Juliana" sort="Schwaab, Juliana" uniqKey="Schwaab J" first="Juliana" last="Schwaab">Juliana Schwaab</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Hematology and Oncology, University Hospital Mannheim, Mannheim</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Karlsruhe</region>
<settlement type="city">Mannheim</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jawhar, Mohamad" sort="Jawhar, Mohamad" uniqKey="Jawhar M" first="Mohamad" last="Jawhar">Mohamad Jawhar</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Hematology and Oncology, University Hospital Mannheim, Mannheim</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Karlsruhe</region>
<settlement type="city">Mannheim</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Reiter, Andreas" sort="Reiter, Andreas" uniqKey="Reiter A" first="Andreas" last="Reiter">Andreas Reiter</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Hematology and Oncology, University Hospital Mannheim, Mannheim</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Karlsruhe</region>
<settlement type="city">Mannheim</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Castells, Mariana" sort="Castells, Mariana" uniqKey="Castells M" first="Mariana" last="Castells">Mariana Castells</name>
<affiliation><nlm:affiliation>Brigham and Women's Hospital, Mastocytosis Center, Harvard Medical School, Boston, Mass.</nlm:affiliation>
<wicri:noCountry code="subField">Mass</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Sperr, Wolfgang R" sort="Sperr, Wolfgang R" uniqKey="Sperr W" first="Wolfgang R" last="Sperr">Wolfgang R. Sperr</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine I, Division of Haematology and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Internal Medicine I, Division of Haematology and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kluin Nelemans, Hanneke C" sort="Kluin Nelemans, Hanneke C" uniqKey="Kluin Nelemans H" first="Hanneke C" last="Kluin-Nelemans">Hanneke C. Kluin-Nelemans</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Haematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Haematology, University Medical Center Groningen, University of Groningen, Groningen</wicri:regionArea>
<placeName><settlement type="city">Groningue</settlement>
<region nuts="2" type="province">Groningue (province)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hermine, Olivier" sort="Hermine, Olivier" uniqKey="Hermine O" first="Olivier" last="Hermine">Olivier Hermine</name>
<affiliation wicri:level="4"><nlm:affiliation>Imagine Institute Université Paris Descartes, Sorbonne, Paris Cité, Centre national de référence des mastocytoses, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Imagine Institute Université Paris Descartes, Sorbonne, Paris Cité, Centre national de référence des mastocytoses, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
<orgName type="university">Université Paris-Descartes</orgName>
</affiliation>
</author>
<author><name sortKey="Gotlib, Jason" sort="Gotlib, Jason" uniqKey="Gotlib J" first="Jason" last="Gotlib">Jason Gotlib</name>
<affiliation><nlm:affiliation>Stanford Cancer Institute/Stanford University School of Medicine, Stanford, Calif.</nlm:affiliation>
<wicri:noCountry code="subField">Calif</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Zanotti, Roberta" sort="Zanotti, Roberta" uniqKey="Zanotti R" first="Roberta" last="Zanotti">Roberta Zanotti</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Medicine, Section of Hematology, University of Verona, Verona</wicri:regionArea>
<wicri:noRegion>Verona</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Broesby Olsen, Sigurd" sort="Broesby Olsen, Sigurd" uniqKey="Broesby Olsen S" first="Sigurd" last="Broesby-Olsen">Sigurd Broesby-Olsen</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark.</nlm:affiliation>
<country xml:lang="fr">Danemark</country>
<wicri:regionArea>Department of Dermatology and Allergy Centre, Odense University Hospital, Odense</wicri:regionArea>
<wicri:noRegion>Odense</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Horny, Hans Peter" sort="Horny, Hans Peter" uniqKey="Horny H" first="Hans-Peter" last="Horny">Hans-Peter Horny</name>
<affiliation wicri:level="3"><nlm:affiliation>Institute of Pathology, Ludwig-Maximilian-University, Munich, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute of Pathology, Ludwig-Maximilian-University, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Triggiani, Massimo" sort="Triggiani, Massimo" uniqKey="Triggiani M" first="Massimo" last="Triggiani">Massimo Triggiani</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Division of Allergy and Clinical Immunology, University of Salerno, Salerno</wicri:regionArea>
<wicri:noRegion>Salerno</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Siebenhaar, Frank" sort="Siebenhaar, Frank" uniqKey="Siebenhaar F" first="Frank" last="Siebenhaar">Frank Siebenhaar</name>
<affiliation wicri:level="3"><nlm:affiliation>Dermatological Allergology, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Dermatological Allergology, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, Berlin</wicri:regionArea>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Orfao, Alberto" sort="Orfao, Alberto" uniqKey="Orfao A" first="Alberto" last="Orfao">Alberto Orfao</name>
<affiliation wicri:level="1"><nlm:affiliation>Servicio Central de Citometria, Centro de Investigacion del Cancer (IBMCC; CSIC/USAL), IBSAL, CIBERONC and Department of Medicine, University of Salamanca, Salamanca, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Servicio Central de Citometria, Centro de Investigacion del Cancer (IBMCC; CSIC/USAL), IBSAL, CIBERONC and Department of Medicine, University of Salamanca, Salamanca</wicri:regionArea>
<wicri:noRegion>Salamanca</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Metcalfe, Dean D" sort="Metcalfe, Dean D" uniqKey="Metcalfe D" first="Dean D" last="Metcalfe">Dean D. Metcalfe</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology & Allergy, Charité Universitätsmedizin Berlin, Berlin, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Dermatology & Allergy, Charité Universitätsmedizin Berlin, Berlin</wicri:regionArea>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Arock, Michel" sort="Arock, Michel" uniqKey="Arock M" first="Michel" last="Arock">Michel Arock</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Hematological Biology, Pitié-Salpêtrière Hospital, Pierre et Marie Curie University (UPMC), Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Hematological Biology, Pitié-Salpêtrière Hospital, Pierre et Marie Curie University (UPMC), Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hartmann, Karin" sort="Hartmann, Karin" uniqKey="Hartmann K" first="Karin" last="Hartmann">Karin Hartmann</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Allergy, Department of Dermatology, and Department of Biomedicine, University of Basel, Basel, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Division of Allergy, Department of Dermatology, and Department of Biomedicine, University of Basel, Basel</wicri:regionArea>
<wicri:noRegion>Basel</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32561389</idno>
<idno type="pmid">32561389</idno>
<idno type="doi">10.1016/j.jaci.2020.06.009</idno>
<idno type="pmc">PMC7297685</idno>
<idno type="wicri:Area/Main/Corpus">000C96</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000C96</idno>
<idno type="wicri:Area/Main/Curation">000C96</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000C96</idno>
<idno type="wicri:Area/Main/Exploration">000C96</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions.</title>
<author><name sortKey="Valent, Peter" sort="Valent, Peter" uniqKey="Valent P" first="Peter" last="Valent">Peter Valent</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine I, Division of Haematology and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria. Electronic address: peter.valent@meduniwien.ac.at.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Internal Medicine I, Division of Haematology and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Akin, Cem" sort="Akin, Cem" uniqKey="Akin C" first="Cem" last="Akin">Cem Akin</name>
<affiliation><nlm:affiliation>Division of Allergy and Clinical Immunology, University of Michigan, Ann Arbor, Mich.</nlm:affiliation>
<wicri:noCountry code="subField">Mich</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Bonadonna, Patrizia" sort="Bonadonna, Patrizia" uniqKey="Bonadonna P" first="Patrizia" last="Bonadonna">Patrizia Bonadonna</name>
<affiliation wicri:level="1"><nlm:affiliation>Allergy Unit, Verona University Hospital, Verona, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Allergy Unit, Verona University Hospital, Verona</wicri:regionArea>
<wicri:noRegion>Verona</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brockow, Knut" sort="Brockow, Knut" uniqKey="Brockow K" first="Knut" last="Brockow">Knut Brockow</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Dermatology and Allergy Biederstein, Technical University of Munich, Munich, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Dermatology and Allergy Biederstein, Technical University of Munich, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
<orgName type="university">Université Louis-et-Maximilien de Munich</orgName>
</affiliation>
</author>
<author><name sortKey="Niedoszytko, Marek" sort="Niedoszytko, Marek" uniqKey="Niedoszytko M" first="Marek" last="Niedoszytko">Marek Niedoszytko</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Allergology, Medical University of Gdansk, Gdansk, Poland.</nlm:affiliation>
<country xml:lang="fr">Pologne</country>
<wicri:regionArea>Department of Allergology, Medical University of Gdansk, Gdansk</wicri:regionArea>
<wicri:noRegion>Gdansk</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Nedoszytko, Boguslaw" sort="Nedoszytko, Boguslaw" uniqKey="Nedoszytko B" first="Boguslaw" last="Nedoszytko">Boguslaw Nedoszytko</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, Medical University of Gdansk, Gdansk, Poland.</nlm:affiliation>
<country xml:lang="fr">Pologne</country>
<wicri:regionArea>Department of Dermatology, Medical University of Gdansk, Gdansk</wicri:regionArea>
<wicri:noRegion>Gdansk</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Butterfield, Joseph H" sort="Butterfield, Joseph H" uniqKey="Butterfield J" first="Joseph H" last="Butterfield">Joseph H. Butterfield</name>
<affiliation><nlm:affiliation>Mayo Clinic, Division of Allergic Diseases, Rochester, Minn.</nlm:affiliation>
<wicri:noCountry code="subField">Minn</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Alvarez Twose, Ivan" sort="Alvarez Twose, Ivan" uniqKey="Alvarez Twose I" first="Ivan" last="Alvarez-Twose">Ivan Alvarez-Twose</name>
<affiliation wicri:level="1"><nlm:affiliation>Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast) and CIBERONC, Hospital Virgen del Valle, Toledo, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast) and CIBERONC, Hospital Virgen del Valle, Toledo</wicri:regionArea>
<wicri:noRegion>Toledo</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sotlar, Karl" sort="Sotlar, Karl" uniqKey="Sotlar K" first="Karl" last="Sotlar">Karl Sotlar</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Pathology, Paracelsus Medical University Salzburg, Salzburg, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Institute of Pathology, Paracelsus Medical University Salzburg, Salzburg</wicri:regionArea>
<wicri:noRegion>Salzburg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schwaab, Juliana" sort="Schwaab, Juliana" uniqKey="Schwaab J" first="Juliana" last="Schwaab">Juliana Schwaab</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Hematology and Oncology, University Hospital Mannheim, Mannheim</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Karlsruhe</region>
<settlement type="city">Mannheim</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jawhar, Mohamad" sort="Jawhar, Mohamad" uniqKey="Jawhar M" first="Mohamad" last="Jawhar">Mohamad Jawhar</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Hematology and Oncology, University Hospital Mannheim, Mannheim</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Karlsruhe</region>
<settlement type="city">Mannheim</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Reiter, Andreas" sort="Reiter, Andreas" uniqKey="Reiter A" first="Andreas" last="Reiter">Andreas Reiter</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Hematology and Oncology, University Hospital Mannheim, Mannheim</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Karlsruhe</region>
<settlement type="city">Mannheim</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Castells, Mariana" sort="Castells, Mariana" uniqKey="Castells M" first="Mariana" last="Castells">Mariana Castells</name>
<affiliation><nlm:affiliation>Brigham and Women's Hospital, Mastocytosis Center, Harvard Medical School, Boston, Mass.</nlm:affiliation>
<wicri:noCountry code="subField">Mass</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Sperr, Wolfgang R" sort="Sperr, Wolfgang R" uniqKey="Sperr W" first="Wolfgang R" last="Sperr">Wolfgang R. Sperr</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine I, Division of Haematology and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Internal Medicine I, Division of Haematology and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kluin Nelemans, Hanneke C" sort="Kluin Nelemans, Hanneke C" uniqKey="Kluin Nelemans H" first="Hanneke C" last="Kluin-Nelemans">Hanneke C. Kluin-Nelemans</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Haematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Haematology, University Medical Center Groningen, University of Groningen, Groningen</wicri:regionArea>
<placeName><settlement type="city">Groningue</settlement>
<region nuts="2" type="province">Groningue (province)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hermine, Olivier" sort="Hermine, Olivier" uniqKey="Hermine O" first="Olivier" last="Hermine">Olivier Hermine</name>
<affiliation wicri:level="4"><nlm:affiliation>Imagine Institute Université Paris Descartes, Sorbonne, Paris Cité, Centre national de référence des mastocytoses, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Imagine Institute Université Paris Descartes, Sorbonne, Paris Cité, Centre national de référence des mastocytoses, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
<orgName type="university">Université Paris-Descartes</orgName>
</affiliation>
</author>
<author><name sortKey="Gotlib, Jason" sort="Gotlib, Jason" uniqKey="Gotlib J" first="Jason" last="Gotlib">Jason Gotlib</name>
<affiliation><nlm:affiliation>Stanford Cancer Institute/Stanford University School of Medicine, Stanford, Calif.</nlm:affiliation>
<wicri:noCountry code="subField">Calif</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Zanotti, Roberta" sort="Zanotti, Roberta" uniqKey="Zanotti R" first="Roberta" last="Zanotti">Roberta Zanotti</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Medicine, Section of Hematology, University of Verona, Verona</wicri:regionArea>
<wicri:noRegion>Verona</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Broesby Olsen, Sigurd" sort="Broesby Olsen, Sigurd" uniqKey="Broesby Olsen S" first="Sigurd" last="Broesby-Olsen">Sigurd Broesby-Olsen</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark.</nlm:affiliation>
<country xml:lang="fr">Danemark</country>
<wicri:regionArea>Department of Dermatology and Allergy Centre, Odense University Hospital, Odense</wicri:regionArea>
<wicri:noRegion>Odense</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Horny, Hans Peter" sort="Horny, Hans Peter" uniqKey="Horny H" first="Hans-Peter" last="Horny">Hans-Peter Horny</name>
<affiliation wicri:level="3"><nlm:affiliation>Institute of Pathology, Ludwig-Maximilian-University, Munich, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute of Pathology, Ludwig-Maximilian-University, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Triggiani, Massimo" sort="Triggiani, Massimo" uniqKey="Triggiani M" first="Massimo" last="Triggiani">Massimo Triggiani</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Division of Allergy and Clinical Immunology, University of Salerno, Salerno</wicri:regionArea>
<wicri:noRegion>Salerno</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Siebenhaar, Frank" sort="Siebenhaar, Frank" uniqKey="Siebenhaar F" first="Frank" last="Siebenhaar">Frank Siebenhaar</name>
<affiliation wicri:level="3"><nlm:affiliation>Dermatological Allergology, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Dermatological Allergology, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, Berlin</wicri:regionArea>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Orfao, Alberto" sort="Orfao, Alberto" uniqKey="Orfao A" first="Alberto" last="Orfao">Alberto Orfao</name>
<affiliation wicri:level="1"><nlm:affiliation>Servicio Central de Citometria, Centro de Investigacion del Cancer (IBMCC; CSIC/USAL), IBSAL, CIBERONC and Department of Medicine, University of Salamanca, Salamanca, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Servicio Central de Citometria, Centro de Investigacion del Cancer (IBMCC; CSIC/USAL), IBSAL, CIBERONC and Department of Medicine, University of Salamanca, Salamanca</wicri:regionArea>
<wicri:noRegion>Salamanca</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Metcalfe, Dean D" sort="Metcalfe, Dean D" uniqKey="Metcalfe D" first="Dean D" last="Metcalfe">Dean D. Metcalfe</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology & Allergy, Charité Universitätsmedizin Berlin, Berlin, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Dermatology & Allergy, Charité Universitätsmedizin Berlin, Berlin</wicri:regionArea>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Arock, Michel" sort="Arock, Michel" uniqKey="Arock M" first="Michel" last="Arock">Michel Arock</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Hematological Biology, Pitié-Salpêtrière Hospital, Pierre et Marie Curie University (UPMC), Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Hematological Biology, Pitié-Salpêtrière Hospital, Pierre et Marie Curie University (UPMC), Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hartmann, Karin" sort="Hartmann, Karin" uniqKey="Hartmann K" first="Karin" last="Hartmann">Karin Hartmann</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Allergy, Department of Dermatology, and Department of Biomedicine, University of Basel, Basel, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Division of Allergy, Department of Dermatology, and Department of Biomedicine, University of Basel, Basel</wicri:regionArea>
<wicri:noRegion>Basel</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">The Journal of allergy and clinical immunology</title>
<idno type="eISSN">1097-6825</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Betacoronavirus (immunology)</term>
<term>Betacoronavirus (pathogenicity)</term>
<term>Comorbidity (MeSH)</term>
<term>Coronavirus Infections (diagnosis)</term>
<term>Coronavirus Infections (epidemiology)</term>
<term>Coronavirus Infections (pathology)</term>
<term>Diphosphonates (therapeutic use)</term>
<term>Disease Management (MeSH)</term>
<term>Expert Testimony (MeSH)</term>
<term>Glucocorticoids (adverse effects)</term>
<term>Histamine Antagonists (therapeutic use)</term>
<term>Humans (MeSH)</term>
<term>Immunosuppressive Agents (adverse effects)</term>
<term>Mast Cells (drug effects)</term>
<term>Mast Cells (immunology)</term>
<term>Mast Cells (pathology)</term>
<term>Mastocytosis, Cutaneous (diagnosis)</term>
<term>Mastocytosis, Cutaneous (drug therapy)</term>
<term>Mastocytosis, Cutaneous (epidemiology)</term>
<term>Mastocytosis, Cutaneous (pathology)</term>
<term>Mastocytosis, Systemic (diagnosis)</term>
<term>Mastocytosis, Systemic (drug therapy)</term>
<term>Mastocytosis, Systemic (epidemiology)</term>
<term>Mastocytosis, Systemic (pathology)</term>
<term>Myeloablative Agonists (adverse effects)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (diagnosis)</term>
<term>Pneumonia, Viral (epidemiology)</term>
<term>Pneumonia, Viral (pathology)</term>
<term>Precision Medicine (methods)</term>
<term>Risk Factors (MeSH)</term>
<term>Vitamin D (therapeutic use)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Agonistes myélo-ablatifs (effets indésirables)</term>
<term>Antihistaminiques (usage thérapeutique)</term>
<term>Betacoronavirus (immunologie)</term>
<term>Betacoronavirus (pathogénicité)</term>
<term>Comorbidité (MeSH)</term>
<term>Diphosphonates (usage thérapeutique)</term>
<term>Expertise (MeSH)</term>
<term>Facteurs de risque (MeSH)</term>
<term>Glucocorticoïdes (effets indésirables)</term>
<term>Humains (MeSH)</term>
<term>Immunosuppresseurs (effets indésirables)</term>
<term>Infections à coronavirus (anatomopathologie)</term>
<term>Infections à coronavirus (diagnostic)</term>
<term>Infections à coronavirus (épidémiologie)</term>
<term>Mastocytes (anatomopathologie)</term>
<term>Mastocytes (effets des médicaments et des substances chimiques)</term>
<term>Mastocytes (immunologie)</term>
<term>Mastocytose cutanée (anatomopathologie)</term>
<term>Mastocytose cutanée (diagnostic)</term>
<term>Mastocytose cutanée (traitement médicamenteux)</term>
<term>Mastocytose cutanée (épidémiologie)</term>
<term>Mastocytose généralisée (anatomopathologie)</term>
<term>Mastocytose généralisée (diagnostic)</term>
<term>Mastocytose généralisée (traitement médicamenteux)</term>
<term>Mastocytose généralisée (épidémiologie)</term>
<term>Médecine de précision (méthodes)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (anatomopathologie)</term>
<term>Pneumopathie virale (diagnostic)</term>
<term>Pneumopathie virale (épidémiologie)</term>
<term>Prise en charge de la maladie (MeSH)</term>
<term>Vitamine D (usage thérapeutique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Glucocorticoids</term>
<term>Immunosuppressive Agents</term>
<term>Myeloablative Agonists</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Diphosphonates</term>
<term>Histamine Antagonists</term>
<term>Vitamin D</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Mastocytes</term>
<term>Mastocytose cutanée</term>
<term>Mastocytose généralisée</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coronavirus Infections</term>
<term>Mastocytosis, Cutaneous</term>
<term>Mastocytosis, Systemic</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Mastocytose cutanée</term>
<term>Mastocytose généralisée</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Mast Cells</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Mastocytosis, Cutaneous</term>
<term>Mastocytosis, Systemic</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Mastocytes</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Agonistes myélo-ablatifs</term>
<term>Glucocorticoïdes</term>
<term>Immunosuppresseurs</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Mastocytosis, Cutaneous</term>
<term>Mastocytosis, Systemic</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Betacoronavirus</term>
<term>Mastocytes</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Betacoronavirus</term>
<term>Mast Cells</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Precision Medicine</term>
</keywords>
<keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Médecine de précision</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Mast Cells</term>
<term>Mastocytosis, Cutaneous</term>
<term>Mastocytosis, Systemic</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Mastocytose cutanée</term>
<term>Mastocytose généralisée</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antihistaminiques</term>
<term>Diphosphonates</term>
<term>Vitamine D</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Mastocytose cutanée</term>
<term>Mastocytose généralisée</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Comorbidity</term>
<term>Disease Management</term>
<term>Expert Testimony</term>
<term>Humans</term>
<term>Pandemics</term>
<term>Risk Factors</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Comorbidité</term>
<term>Expertise</term>
<term>Facteurs de risque</term>
<term>Humains</term>
<term>Pandémies</term>
<term>Prise en charge de la maladie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The coronavirus disease 2019 (COVID-19) (caused by severe acute respiratory syndrome coronavirus 2) pandemic has massively distorted our health care systems and caused catastrophic consequences in our affected communities. The number of victims continues to increase, and patients at risk can only be protected to a degree, because the virulent state may be asymptomatic. Risk factors concerning COVID-19-induced morbidity and mortality include advanced age, an impaired immune system, cardiovascular or pulmonary diseases, obesity, diabetes mellitus, and cancer treated with chemotherapy. Here, we discuss the risk and impact of COVID-19 in patients with mastocytosis and mast cell activation syndromes. Because no published data are yet available, expert opinions are, by necessity, based on case experience and reports from patients. Although the overall risk to acquire the severe acute respiratory syndrome coronavirus 2 may not be elevated in mast cell disease, certain conditions may increase the risk of infected patients to develop severe COVID-19. These factors include certain comorbidities, mast cell activation-related events affecting the cardiovascular or bronchopulmonary system, and chemotherapy or immunosuppressive drugs. Therefore, such treatments should be carefully evaluated on a case-by-case basis during a COVID-19 infection. In contrast, other therapies, such as anti-mediator-type drugs, venom immunotherapy, or vitamin D, should be continued. Overall, patients with mast cell disorders should follow the general and local guidelines in the COVID-19 pandemic and advice from their medical provider.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32561389</PMID>
<DateCompleted><Year>2020</Year>
<Month>08</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>08</Month>
<Day>25</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-6825</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>146</Volume>
<Issue>2</Issue>
<PubDate><Year>2020</Year>
<Month>08</Month>
</PubDate>
</JournalIssue>
<Title>The Journal of allergy and clinical immunology</Title>
<ISOAbbreviation>J. Allergy Clin. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions.</ArticleTitle>
<Pagination><MedlinePgn>300-306</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0091-6749(20)30839-3</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaci.2020.06.009</ELocationID>
<Abstract><AbstractText>The coronavirus disease 2019 (COVID-19) (caused by severe acute respiratory syndrome coronavirus 2) pandemic has massively distorted our health care systems and caused catastrophic consequences in our affected communities. The number of victims continues to increase, and patients at risk can only be protected to a degree, because the virulent state may be asymptomatic. Risk factors concerning COVID-19-induced morbidity and mortality include advanced age, an impaired immune system, cardiovascular or pulmonary diseases, obesity, diabetes mellitus, and cancer treated with chemotherapy. Here, we discuss the risk and impact of COVID-19 in patients with mastocytosis and mast cell activation syndromes. Because no published data are yet available, expert opinions are, by necessity, based on case experience and reports from patients. Although the overall risk to acquire the severe acute respiratory syndrome coronavirus 2 may not be elevated in mast cell disease, certain conditions may increase the risk of infected patients to develop severe COVID-19. These factors include certain comorbidities, mast cell activation-related events affecting the cardiovascular or bronchopulmonary system, and chemotherapy or immunosuppressive drugs. Therefore, such treatments should be carefully evaluated on a case-by-case basis during a COVID-19 infection. In contrast, other therapies, such as anti-mediator-type drugs, venom immunotherapy, or vitamin D, should be continued. Overall, patients with mast cell disorders should follow the general and local guidelines in the COVID-19 pandemic and advice from their medical provider.</AbstractText>
<CopyrightInformation>Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Valent</LastName>
<ForeName>Peter</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Department of Internal Medicine I, Division of Haematology and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria. Electronic address: peter.valent@meduniwien.ac.at.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Akin</LastName>
<ForeName>Cem</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Division of Allergy and Clinical Immunology, University of Michigan, Ann Arbor, Mich.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bonadonna</LastName>
<ForeName>Patrizia</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Allergy Unit, Verona University Hospital, Verona, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Brockow</LastName>
<ForeName>Knut</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Department of Dermatology and Allergy Biederstein, Technical University of Munich, Munich, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Niedoszytko</LastName>
<ForeName>Marek</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Allergology, Medical University of Gdansk, Gdansk, Poland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nedoszytko</LastName>
<ForeName>Boguslaw</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Department of Dermatology, Medical University of Gdansk, Gdansk, Poland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Butterfield</LastName>
<ForeName>Joseph H</ForeName>
<Initials>JH</Initials>
<AffiliationInfo><Affiliation>Mayo Clinic, Division of Allergic Diseases, Rochester, Minn.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Alvarez-Twose</LastName>
<ForeName>Ivan</ForeName>
<Initials>I</Initials>
<AffiliationInfo><Affiliation>Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast) and CIBERONC, Hospital Virgen del Valle, Toledo, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sotlar</LastName>
<ForeName>Karl</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Institute of Pathology, Paracelsus Medical University Salzburg, Salzburg, Austria.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Schwaab</LastName>
<ForeName>Juliana</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jawhar</LastName>
<ForeName>Mohamad</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Reiter</LastName>
<ForeName>Andreas</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Castells</LastName>
<ForeName>Mariana</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Brigham and Women's Hospital, Mastocytosis Center, Harvard Medical School, Boston, Mass.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sperr</LastName>
<ForeName>Wolfgang R</ForeName>
<Initials>WR</Initials>
<AffiliationInfo><Affiliation>Department of Internal Medicine I, Division of Haematology and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kluin-Nelemans</LastName>
<ForeName>Hanneke C</ForeName>
<Initials>HC</Initials>
<AffiliationInfo><Affiliation>Department of Haematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hermine</LastName>
<ForeName>Olivier</ForeName>
<Initials>O</Initials>
<AffiliationInfo><Affiliation>Imagine Institute Université Paris Descartes, Sorbonne, Paris Cité, Centre national de référence des mastocytoses, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gotlib</LastName>
<ForeName>Jason</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Stanford Cancer Institute/Stanford University School of Medicine, Stanford, Calif.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zanotti</LastName>
<ForeName>Roberta</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Broesby-Olsen</LastName>
<ForeName>Sigurd</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Horny</LastName>
<ForeName>Hans-Peter</ForeName>
<Initials>HP</Initials>
<AffiliationInfo><Affiliation>Institute of Pathology, Ludwig-Maximilian-University, Munich, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Triggiani</LastName>
<ForeName>Massimo</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Division of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Siebenhaar</LastName>
<ForeName>Frank</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Dermatological Allergology, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Orfao</LastName>
<ForeName>Alberto</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Servicio Central de Citometria, Centro de Investigacion del Cancer (IBMCC; CSIC/USAL), IBSAL, CIBERONC and Department of Medicine, University of Salamanca, Salamanca, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Metcalfe</LastName>
<ForeName>Dean D</ForeName>
<Initials>DD</Initials>
<AffiliationInfo><Affiliation>Department of Dermatology & Allergy, Charité Universitätsmedizin Berlin, Berlin, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Arock</LastName>
<ForeName>Michel</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Hematological Biology, Pitié-Salpêtrière Hospital, Pierre et Marie Curie University (UPMC), Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hartmann</LastName>
<ForeName>Karin</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Division of Allergy, Department of Dermatology, and Department of Biomedicine, University of Basel, Basel, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>06</Month>
<Day>17</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Allergy Clin Immunol</MedlineTA>
<NlmUniqueID>1275002</NlmUniqueID>
<ISSNLinking>0091-6749</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004164">Diphosphonates</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006633">Histamine Antagonists</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019653">Myeloablative Agonists</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>1406-16-2</RegistryNumber>
<NameOfSubstance UI="D014807">Vitamin D</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004164" MajorTopicYN="N">Diphosphonates</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019468" MajorTopicYN="Y">Disease Management</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005104" MajorTopicYN="N">Expert Testimony</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006633" MajorTopicYN="N">Histamine Antagonists</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008407" MajorTopicYN="N">Mast Cells</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D034701" MajorTopicYN="N">Mastocytosis, Cutaneous</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D034721" MajorTopicYN="N">Mastocytosis, Systemic</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019653" MajorTopicYN="N">Myeloablative Agonists</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057285" MajorTopicYN="N">Precision Medicine</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014807" MajorTopicYN="N">Vitamin D</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword>
<Keyword MajorTopicYN="Y">KIT D816V</Keyword>
<Keyword MajorTopicYN="Y">Mast cells</Keyword>
<Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword>
<Keyword MajorTopicYN="Y">coronavirus</Keyword>
<Keyword MajorTopicYN="Y">mast cell activation syndrome</Keyword>
<Keyword MajorTopicYN="Y">mastocytosis</Keyword>
<Keyword MajorTopicYN="Y">tryptase</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>05</Month>
<Day>13</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>06</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>06</Month>
<Day>10</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>6</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>8</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>6</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32561389</ArticleId>
<ArticleId IdType="pii">S0091-6749(20)30839-3</ArticleId>
<ArticleId IdType="doi">10.1016/j.jaci.2020.06.009</ArticleId>
<ArticleId IdType="pmc">PMC7297685</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Allemagne</li>
<li>Autriche</li>
<li>Danemark</li>
<li>Espagne</li>
<li>France</li>
<li>Italie</li>
<li>Pays-Bas</li>
<li>Pologne</li>
<li>Suisse</li>
</country>
<region><li>Bade-Wurtemberg</li>
<li>Bavière</li>
<li>Berlin</li>
<li>District de Haute-Bavière</li>
<li>District de Karlsruhe</li>
<li>Groningue (province)</li>
<li>Vienne (Autriche)</li>
<li>Île-de-France</li>
</region>
<settlement><li>Berlin</li>
<li>Groningue</li>
<li>Mannheim</li>
<li>Munich</li>
<li>Paris</li>
<li>Vienne (Autriche)</li>
</settlement>
<orgName><li>Université Louis-et-Maximilien de Munich</li>
<li>Université Paris-Descartes</li>
</orgName>
</list>
<tree><noCountry><name sortKey="Akin, Cem" sort="Akin, Cem" uniqKey="Akin C" first="Cem" last="Akin">Cem Akin</name>
<name sortKey="Butterfield, Joseph H" sort="Butterfield, Joseph H" uniqKey="Butterfield J" first="Joseph H" last="Butterfield">Joseph H. Butterfield</name>
<name sortKey="Castells, Mariana" sort="Castells, Mariana" uniqKey="Castells M" first="Mariana" last="Castells">Mariana Castells</name>
<name sortKey="Gotlib, Jason" sort="Gotlib, Jason" uniqKey="Gotlib J" first="Jason" last="Gotlib">Jason Gotlib</name>
</noCountry>
<country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Valent, Peter" sort="Valent, Peter" uniqKey="Valent P" first="Peter" last="Valent">Peter Valent</name>
</region>
<name sortKey="Sotlar, Karl" sort="Sotlar, Karl" uniqKey="Sotlar K" first="Karl" last="Sotlar">Karl Sotlar</name>
<name sortKey="Sperr, Wolfgang R" sort="Sperr, Wolfgang R" uniqKey="Sperr W" first="Wolfgang R" last="Sperr">Wolfgang R. Sperr</name>
</country>
<country name="Italie"><noRegion><name sortKey="Bonadonna, Patrizia" sort="Bonadonna, Patrizia" uniqKey="Bonadonna P" first="Patrizia" last="Bonadonna">Patrizia Bonadonna</name>
</noRegion>
<name sortKey="Triggiani, Massimo" sort="Triggiani, Massimo" uniqKey="Triggiani M" first="Massimo" last="Triggiani">Massimo Triggiani</name>
<name sortKey="Zanotti, Roberta" sort="Zanotti, Roberta" uniqKey="Zanotti R" first="Roberta" last="Zanotti">Roberta Zanotti</name>
</country>
<country name="Allemagne"><region name="Bavière"><name sortKey="Brockow, Knut" sort="Brockow, Knut" uniqKey="Brockow K" first="Knut" last="Brockow">Knut Brockow</name>
</region>
<name sortKey="Horny, Hans Peter" sort="Horny, Hans Peter" uniqKey="Horny H" first="Hans-Peter" last="Horny">Hans-Peter Horny</name>
<name sortKey="Jawhar, Mohamad" sort="Jawhar, Mohamad" uniqKey="Jawhar M" first="Mohamad" last="Jawhar">Mohamad Jawhar</name>
<name sortKey="Metcalfe, Dean D" sort="Metcalfe, Dean D" uniqKey="Metcalfe D" first="Dean D" last="Metcalfe">Dean D. Metcalfe</name>
<name sortKey="Reiter, Andreas" sort="Reiter, Andreas" uniqKey="Reiter A" first="Andreas" last="Reiter">Andreas Reiter</name>
<name sortKey="Schwaab, Juliana" sort="Schwaab, Juliana" uniqKey="Schwaab J" first="Juliana" last="Schwaab">Juliana Schwaab</name>
<name sortKey="Siebenhaar, Frank" sort="Siebenhaar, Frank" uniqKey="Siebenhaar F" first="Frank" last="Siebenhaar">Frank Siebenhaar</name>
</country>
<country name="Pologne"><noRegion><name sortKey="Niedoszytko, Marek" sort="Niedoszytko, Marek" uniqKey="Niedoszytko M" first="Marek" last="Niedoszytko">Marek Niedoszytko</name>
</noRegion>
<name sortKey="Nedoszytko, Boguslaw" sort="Nedoszytko, Boguslaw" uniqKey="Nedoszytko B" first="Boguslaw" last="Nedoszytko">Boguslaw Nedoszytko</name>
</country>
<country name="Espagne"><noRegion><name sortKey="Alvarez Twose, Ivan" sort="Alvarez Twose, Ivan" uniqKey="Alvarez Twose I" first="Ivan" last="Alvarez-Twose">Ivan Alvarez-Twose</name>
</noRegion>
<name sortKey="Orfao, Alberto" sort="Orfao, Alberto" uniqKey="Orfao A" first="Alberto" last="Orfao">Alberto Orfao</name>
</country>
<country name="Pays-Bas"><region name="Groningue (province)"><name sortKey="Kluin Nelemans, Hanneke C" sort="Kluin Nelemans, Hanneke C" uniqKey="Kluin Nelemans H" first="Hanneke C" last="Kluin-Nelemans">Hanneke C. Kluin-Nelemans</name>
</region>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Hermine, Olivier" sort="Hermine, Olivier" uniqKey="Hermine O" first="Olivier" last="Hermine">Olivier Hermine</name>
</region>
<name sortKey="Arock, Michel" sort="Arock, Michel" uniqKey="Arock M" first="Michel" last="Arock">Michel Arock</name>
</country>
<country name="Danemark"><noRegion><name sortKey="Broesby Olsen, Sigurd" sort="Broesby Olsen, Sigurd" uniqKey="Broesby Olsen S" first="Sigurd" last="Broesby-Olsen">Sigurd Broesby-Olsen</name>
</noRegion>
</country>
<country name="Suisse"><noRegion><name sortKey="Hartmann, Karin" sort="Hartmann, Karin" uniqKey="Hartmann K" first="Karin" last="Hartmann">Karin Hartmann</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000713 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000713 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidFranceV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32561389
   |texte=   Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32561389" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidFranceV1

This area was generated with Dilib version V0.6.37.
Data generation: Tue Oct 6 23:31:36 2020. Site generation: Fri Feb 12 22:48:37 2021

	Serveur d'exploration sur la COVID en France
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la COVID en France

Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions.

Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki